Protective efficacy of Eglin C from Hirudo medicinalis against Eimeria papillata-induced coccidiosis

The current study aimed to find a new therapeutic agent from Hirudo medicinalis for murine coccidiosis. Ion-exchange chromatography was performed to separate different fractions of HEA (hirudo extract antigens). Eight different fractions were experimentally tested against murine eimeriosis induced by Eimeria papillate. The oocysts output was counted to determine the most effective fractions. For the five most effective fraction groups, jejunal histological examination and goblet cells count as well as mRNA expression of MUC2 gene using RT-PCR were performed. The data indicated that these fractions significantly decreased the oocysts output and the number of parasite developmental stages, while the goblet cell numbers and the expression of MUC2 were increased. Effective fractions were subjected to SDS-PAGE and proteomic analysis for detection of their bioactive macromolecules. The fractions reveled only a protein at 8 kDa while the results of spectroscopy and bioinformatics identified the protein as Eglin C. The pooled fractions containing Eglin C were tested in vitro to determine its stimulation for the intestinal lymphocyte proliferation and IFN-γ together with IL-6 release in the supernatant. The results showed that higher Eglin C concentrations reduced the stimulation index of lymphocyte proliferation as well as the stimulation index of IFN-γ and IL-6 production. In conclusion, Eglin C protein can be used as a target for therapeutic treatment or as an anti-inflammatory agent for coccidiosis infection.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Hirudo medicinalis extract fractions, identified as the 8 kDa protein Eglin C, reduced oocyst output and parasite developmental stages while increasing goblet-cell counts and MUC2 expression in mice with Eimeria papillate infection, suggesting Eglin C as a coccidiosis therapeutic target.

Explore how this research connects to clinical practice

More peer-reviewed studies in Genomics & Proteomics.

• Leech Salivary Proteome and Transcriptome: 434 Deduced Protein Sequences — Liu Z, Tong X, Su Y, et al. (2019)
• Medicinal Leech Draft Genome — Anticoagulant Gene Survey — Kvist S, Manzano-Marín A, de Carle D, Trontelj P, Siddall ME (2020)
• Leech therapy (Hirudo medicinalis) attenuates testicular damages induced by testicular ischemia/reperfusion in an animal model — Davoodi F et al. (2021)
• New anticoagulant protein from medicinal leech — Manuvera V et al. (2024)
• AIF-1 and RNASET2 Play Complementary Roles in the Innate Immune Response of Medicinal Leech — Baranzini N et al. (2019)
• Medicinal leech antimicrobial peptides lacking toxicity represent a promising alternative strategy to combat antibiotic-resistant pathogens — Grafskaia E et al. (2019)
• Structural insights into thrombolytic activity of destabilase from medicinal leech — Marin E et al. (2023)
• The genome of medicinal leech (Whitmania pigra) and comparative genomic study for exploration of bioactive ingredients — Tong L et al. (2022)
• Medicinal Leech CNS as a Model for Exosome Studies in the Crosstalk between Microglia and Neurons — Raffo-Romero A et al. (2018)
• Transcriptomic profiling and the first spatial expression analysis of candidate genes in the salivary gland of the East Asian medicinal leech, Hirudo nipponia — Kim J et al. (2024)

Browse all ASH-analysed research →